Study of MEDI 507 in the Treatment of Pediatric Patients
Status:
Completed
Trial end date:
2004-08-01
Target enrollment:
Participant gender:
Summary
To assess the safety of escalating dose levels of MEDI-507 in pediatric stem cell and bone
marrow allograft recipients who have at least Grade II GvHD.